and Washington, D.C. (October 18, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced follow-up data supporting excellent long-term safety and efficacy from four of its TAXUS clinical trials. The Company reported results from TAXUS I (four years), TAXUS II (three years), TAXUS IV (three years), and TAXUS VI (two years). The Company made the announcement at the annual Transcatheter Cardiovascular Therapeutics symposium in Washington, D.C.

“The TAXUS clinical results reported today are outstanding and demonstrate the long-term safety and efficacy of paclitaxel-eluting stent technology,